A5071102504- Vitamin C and Antioxidants Research
- Acute Myeloid Leukemia Research
- Retinoids in leukemia and cellular processes
- Microbial Metabolic Engineering and Bioproduction
- Coenzyme Q10 studies and effects
- Acute Lymphoblastic Leukemia research
- Helicobacter pylori-related gastroenterology studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Chronic Myeloid Leukemia Treatments
- Pancreatitis Pathology and Treatment
- Cancer, Hypoxia, and Metabolism
- Immune cells in cancer
- Inflammatory Bowel Disease
- Microscopic Colitis
European Institute of Oncology
2022-2024
Abstract MYC is a key oncogenic driver in multiple tumor types, but concomitantly endows cancer cells with series of vulnerabilities that provide opportunities for targeted pharmacological intervention. For example, drugs suppress mitochondrial respiration selectively kill MYC‐overexpressing cells. Here, we unravel the mechanistic basis this synthetic lethal interaction and exploit it to improve anticancer effects respiratory complex I inhibitor IACS‐010759. In B‐lymphoid cell line, ectopic...
Abstract Background Fibrostenosis represents one of the major clinical complications Crohn’s Disease (CD). However, molecular mechanisms underlying intestinal fibrogenesis remain poorly understood and anti-fibrotic therapy has not yet been developed. Growing evidences supports that oxidative stress epithelial-mesenchymal transition (EMT) process contribute to development progression fibrosis. Here, we assessed role lipids in whether mitochondria dysfunction can support fibrosis formation....
ABSTRACT MYC is a key oncogenic driver and an adverse prognostic factor in multiple types of cancer, including diffuse large B-cell lymphoma (DLBCL). Yet, activation also endows cancer cells with series metabolic dependencies, which can provide strategic points for targeted pharmacological intervention. We recently reported that targeting the mitochondrial electron transport chain (ETC) complex I small molecule inhibitor IACS-010759 selectively killed MYC-overexpressing lymphoid cells. Here,...